Equities

AIM Vaccine Co Ltd

AIM Vaccine Co Ltd

Actions
  • Price (HKD)4.67
  • Today's Change-2.29 / -32.90%
  • Shares traded206.20k
  • 1 Year change-50.05%
  • Beta--
Data delayed at least 15 minutes, as of Aug 23 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments736798747
Total Receivables, Net1,0801,0961,091
Total Inventory510505367
Prepaid expenses335849
Other current assets, total12493104
Total current assets2,4832,5492,359
Property, plant & equipment, net3,6043,6033,020
Goodwill, net271483483
Intangibles, net289306312
Long term investments------
Note receivable - long term0.060.0111
Other long term assets2.583.146.47
Total assets7,2628,8768,072
LIABILITIES
Accounts payable607452
Accrued expenses6980109
Notes payable/short-term debt1,151967397
Current portion long-term debt/capital leases756327
Other current liabilities, total1,2461,067985
Total current liabilities2,6022,2501,570
Total long term debt569369226
Total debt1,7961,399650
Deferred income tax41269492
Minority interest247901807
Other liabilities, total16012785
Total liabilities3,6193,9163,180
SHAREHOLDERS EQUITY
Common stock1,2111,2111,200
Additional paid-in capital------
Retained earnings (accumulated deficit)2,4323,7493,693
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity3,6434,9604,893
Total liabilities & shareholders' equity7,2628,8768,072
Total common shares outstanding1,2111,2111,210
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.